<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30059817</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1879-0852</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>101</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>European journal of cancer (Oxford, England : 1990)</Title>                <ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012.</ArticleTitle>            <Pagination>                <MedlinePgn>134-142</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0959-8049(18)30953-5</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2018.07.003</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The incidence of ductal carcinoma in situ (DCIS) has drastically increased over the past decades. Because DCIS is resected after diagnosis similar to invasive breast cancer, the natural cause and behaviour of DCIS is not well known. We aimed to determine breast cancer-specific survival (BCSS) and overall survival (OS) according to grade in DCIS patients after surgical treatment in the Netherlands.</AbstractText>                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">All DCIS patients diagnosed between 1999 and 2012 were selected from the Netherlands Cancer Registry. The cause of death was obtained from 'Statistics Netherlands'. BCSS and OS were estimated using multivariable Cox regression in the entire cohort and stratified for grades.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 12,256 patients were included, of whom 1509 (12.3%) presented with grade I, 3675 (30.0%) with grade II, 6064 (49.5%) with grade III and 1008 (8.2%) with an unknown grade. During a median follow-up of 7.8 years, 1138 (9.3%) deaths were observed, and 179 (1.5%) were breast cancer-related. Of these, 10 patients had grade I; 46 grade II; 95 grade III and 28 an unknown grade. After adjustment for confounding, grade II and III were related to worse BCSS than grade I with hazard ratios of 1.92 (95% confidence interval [CI]: 0.97-3.81) and 2.14 (95% CI: 1.11-4.12), respectively. No association between grades and OS was observed.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">BCSS and OS in DCIS patients were excellent. Because superior rates were observed for low-grade DCIS, it seems justified to investigate whether active surveillance may be a balanced alternative for conventional surgical treatment.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>van Maaren</LastName>                    <ForeName>M C</ForeName>                    <Initials>MC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; Department of Health Technology &amp; Services Research, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands. Electronic address: m.vanmaaren@iknl.nl.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lagendijk</LastName>                    <ForeName>M</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tilanus-Linthorst</LastName>                    <ForeName>M M A</ForeName>                    <Initials>MMA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>de Munck</LastName>                    <ForeName>L</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; Department of Epidemiology, University of Groningen, University Medical Center Groningen Groningen, the Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pijnappel</LastName>                    <ForeName>R M</ForeName>                    <Initials>RM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Imaging, University Medical Centre Utrecht, Utrecht University, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schmidt</LastName>                    <ForeName>M K</ForeName>                    <Initials>MK</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands; Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wesseling</LastName>                    <ForeName>J</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Koppert</LastName>                    <ForeName>L B</ForeName>                    <Initials>LB</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Siesling</LastName>                    <ForeName>S</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; Department of Health Technology &amp; Services Research, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>28</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Eur J Cancer</MedlineTA>            <NlmUniqueID>9005373</NlmUniqueID>            <ISSNLinking>0959-8049</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer-specific survival</Keyword>            <Keyword MajorTopicYN="N">Breast cancer–related deaths</Keyword>            <Keyword MajorTopicYN="N">Ductal carcinoma in situ</Keyword>            <Keyword MajorTopicYN="N">Population-based study</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>7</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30059817</ArticleId>            <ArticleId IdType="pii">S0959-8049(18)30953-5</ArticleId>            <ArticleId IdType="doi">10.1016/j.ejca.2018.07.003</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>